Navigation Links
PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
Date:11/4/2010

ANNAPOLIS, Md., Nov. 4, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company was awarded four separate grants totaling approximately $850,000 under the Qualifying Therapeutic Discovery Project, enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). The grant is a benefit targeted to small business therapeutic discovery projects that show a potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions.

"We are delighted that PharmAthene was selected as a grant recipient under this program," commented Eric I. Richman, President and Chief Executive Officer.  The Therapeutic Discovery initiative was established to promote the research and development of biomedical programs that show significant potential to produce new and cost-saving therapies, support quality job creation, and increase U.S. competitiveness.  Since its inception, PharmAthene has focused on developing urgently needed, best-in-class, next generation medical countermeasures that offer the potential for improved safety, convenience, and cost-effectiveness, consistent with this imperative.  We look forward to advancing our mission and remain committed to meeting the needs of the U.S. government to ensure the safety and well-being of Americans at home and on the battlefield."

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • rBChE - recombinant butyrylcholinesterase bioscavanger: Protexia® and a second generation Advanced Expression System ("AES") countermeasures for nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there can be no assurance that PharmAthene will satisfy the NYSE Amex continuing listing standards by January 26, 2012, or that during the compliance period the Exchange will not deem PharmAthene's progress toward compliance inadequate.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Announces Pricing of $15 Million Public Offering
2. PharmAthene Announces Proposed Common Stock Offering
3. PharmAthene Announces $3.9 Million Registered Direct Offering
4. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
5. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
6. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
7. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
8. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
9. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
10. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
11. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 ATCC, the premier global ... assist the medical and life science researchers that are ... infection.   CDC website . ... Zika virus is a single-stranded RNA virus of the ... Nile, Dengue and Chikungunya Viruses. Zika virus is transmitted ...
(Date:2/4/2016)... Francisco, CA (PRWEB) , ... February 04, 2016 ... ... of enterprise talent development and compliance training, today announced an interactive FDA ... Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, ... various medical institutions attended a ceremony in late 2015 ... personalized cell therapy in 2016. --> ... Clinical Translation Platform for Personalized Cell Therapy" was hosted ... Cell Production Center, both subsidiaries of Beike Biotechnology Co., ...
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
Breaking Biology News(10 mins):